Benjamin Gartrell, MD
Internal Medicine · Bronx, NYNPI 1043414451
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,314 of the $74,713 with a category attached, or 83.4%. 17 manufacturers reported payments, led by Janssen Global Services, LLC at 27.8% of the total. Reporting peaked in 2024 at $18,220 and has fallen 66.8% since, to $6,045 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 60 payments — averaging $1245.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Global Services, LLC$21K
- Sanofi$12K
- Novartis$8K
- E.r. Squibb & Sons, L.L.C.$7K
- Johnson & Johnson$6K
- Eisai Inc.$5K
- plus $16K from 11 others
Across 1,264 payments — averaging $4889.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.4M
- Novartis$1.3M
- Janssen Research & Development, LLC$765K
- Bayer$515K
- Blue Earth Diagnostics$486K
- AstraZeneca$247K
- plus $1.4M from 16 others
What the payments were for
- Consulting fees$62,31483%
- Speaking & faculty fees$9,25212%
- Travel & lodging$1,6432%
- Food & beverage$1,5042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Global Services, LLC | 14 | $20,770 |
| Sanofi | 2 | $12,088 |
| Novartis | 3 | $8,031 |
| E.r. Squibb & Sons, L.L.C. | 5 | $6,694 |
| Johnson & Johnson | 10 | $6,139 |
| Eisai Inc. | 5 | $4,861 |
| Janssen Scientific Affairs, LLC | 6 | $4,846 |
| Bayer | 4 | $3,476 |
| Astellas Pharma US Inc | 1 | $2,340 |
| AVEO Pharmaceuticals, Inc. | 2 | $1,603 |
| Pfizer | 2 | $1,535 |
| Seagen Inc. | 1 | $1,150 |
| Blue Earth Diagnostics | 1 | $1,063 |
| Exelixis Inc. | 1 | $67 |
| Genentech USA, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,713 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 660 | $1,931,029 |
| ErleadaApalutamide | 37 | $501,184 |
| CabometyxCabozantinib S-Malate | 14 | $364,490 |
| NubeqaDarolutamide | 27 | $357,229 |
| XtandiEnzalutamide | 24 | $313,635 |
| OrgovyxRelugolix | 83 | $224,043 |
| Prednisone | 456 | $1,748 |
| Bicalutamide | 32 | $541 |
| Tamsulosin Hcl | 31 | $507 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $267 |
| Ondansetron Hcl | 13 | $116 |
| Amlodipine Besylate | 21 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,846 | $1,931,029660 claims |
| Johnson & JohnsonErleada | $6,139 | $501,18437 claims |
| Exelixis Inc.Cabometyx | $67 | $364,49014 claims |
| BayerNubeqa | $3,476 | $357,22927 claims |
| Astellas Pharma US IncXtandi | $2,340 | $313,63524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Jason LeiderBronx$694K
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Elizabeth Jenny-AvitalBronx$185K
- Meyer HalberstamBronx$143K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.